Canadian Urological Association best practice report: Bone health in prostate cancer.
作者信息
Lavallée Luke T, McLarty Ryan, Tran Christopher, Breau Rodney H, Richard Patrick, Shayegan Bobby, Danielson Brita, Jammal Marie-Paul, Saad Fred
机构信息
Division of Urology, Department of Surgery, University of Ottawa and Ottawa Hospital Research Institute Epidemiology Program, Ottawa, ON, Canada.
Division of Endocrinology and Metabolism, Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada.
出版信息
Can Urol Assoc J. 2021 Dec;15(12):375-382. doi: 10.5489/cuaj.7660.
Abstract
摘要
相似文献
1
Canadian Urological Association best practice report: Bone health in prostate cancer.加拿大泌尿外科协会最佳实践报告：前列腺癌中的骨骼健康
Can Urol Assoc J. 2021 Dec;15(12):375-382. doi: 10.5489/cuaj.7660.
2
3
Establishment of a urological surgery quality collaborative.建立泌尿外科手术质量协作组。
J Urol. 2010 Dec;184(6):2485-90. doi: 10.1016/j.juro.2010.08.015. Epub 2010 Oct 18.
4
Qualitative Review of Clinical Guidelines for Medical and Surgical Management of Urolithiasis: Consensus and Controversy 2020.2020 年尿石症医学和外科治疗临床指南的定性评价：共识与争议
J Urol. 2021 Apr;205(4):999-1008. doi: 10.1097/JU.0000000000001478. Epub 2020 Dec 7.
5
6
Regional collaboration to improve radiographic staging practices among men with early stage prostate cancer.区域合作以改善早期前列腺癌男性的影像学分期实践。
J Urol. 2011 Sep;186(3):844-9. doi: 10.1016/j.juro.2011.04.078. Epub 2011 Jul 23.
7
Familiarity and self-reported compliance with American Urological Association best practice recommendations for use of thromboembolic prophylaxis among American Urological Association members.美国泌尿外科学会会员对血栓栓塞预防最佳实践建议的熟悉程度和自我报告的依从性。
J Urol. 2013 Sep;190(3):992-8. doi: 10.1016/j.juro.2013.03.076. Epub 2013 Mar 26.
8
Age-specific reference range of prostate-specific antigen and prostate cancer detection in population-based screening cohort in Japan: verification of Japanese Urological Association Guideline for prostate cancer.日本基于人群的筛查队列中前列腺特异性抗原的年龄特异性参考范围与前列腺癌检测：对日本泌尿外科学会前列腺癌指南的验证
Int J Urol. 2014 Nov;21(11):1120-5. doi: 10.1111/iju.12523. Epub 2014 Jun 15.
9
Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer.加拿大泌尿外科学会 - 加拿大泌尿肿瘤学组关于转移性去势初治和去势敏感性前列腺癌的指南
Can Urol Assoc J. 2020 Feb;14(2):17-23. doi: 10.5489/cuaj.6384. Epub 2019 Dec 5.
10
Canadian Urological Association best practice report: Diagnosis and management of sporadic angiomyolipomas.加拿大泌尿外科协会最佳实践报告：散发性肾血管平滑肌脂肪瘤的诊断与管理
Can Urol Assoc J. 2020 Nov;14(11):E527-E536. doi: 10.5489/cuaj.6942.
引用本文的文献
1
Safety and Efficacy of Carbon-Ion Radiotherapy for Elderly Patients with High-Risk Prostate Cancer.碳离子放疗治疗老年高危前列腺癌患者的安全性和有效性
Cancers (Basel). 2022 Aug 19;14(16):4015. doi: 10.3390/cancers14164015.
2
Implementing and Evaluating the Impact of BoneRx: A Healthy Bone Prescription for Men with Prostate Cancer Initiating Androgen Deprivation Therapy.实施与评估BoneRx的影响：为开始雄激素剥夺治疗的前列腺癌男性提供的健康骨骼处方
J Clin Med. 2022 May 11;11(10):2703. doi: 10.3390/jcm11102703.
本文引用的文献
1
Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis.评估接受雄激素受体抑制剂治疗的前列腺癌男性的跌倒和骨折风险：系统评价和荟萃分析。
JAMA Netw Open. 2020 Nov 2;3(11):e2025826. doi: 10.1001/jamanetworkopen.2020.25826.
2
A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer.一项比较骨转移乳腺癌或去势抵抗性前列腺癌患者接受 4 周和 12 周骨靶向药物治疗的随机临床试验。
Eur J Cancer. 2021 Jan;142:132-140. doi: 10.1016/j.ejca.2020.08.019. Epub 2020 Oct 3.
3
Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.非典型股骨骨折风险与双膦酸盐预防脆性骨折。
N Engl J Med. 2020 Aug 20;383(8):743-753. doi: 10.1056/NEJMoa1916525.
4
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE.美国临床内分泌医师协会/美国内分泌学会 2020 年绝经后骨质疏松症诊断和治疗临床实践指南更新版
Endocr Pract. 2020 May;26(Suppl 1):1-46. doi: 10.4158/GL-2020-0524SUPPL.
5
Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion.前列腺癌病程中的骨骼健康管理：基于专家小组意见的证据综述
ESMO Open. 2020 Mar;5(2). doi: 10.1136/esmoopen-2019-000652.
6
Bone Health and Bone-Targeted Therapies for Prostate Cancer: American Society of Clinical Oncology Endorsement Summary of a Cancer Care Ontario Guideline.前列腺癌的骨骼健康与骨靶向治疗：美国临床肿瘤学会对安大略癌症护理指南的认可总结
JCO Oncol Pract. 2020 Jul;16(7):389-393. doi: 10.1200/JOP.19.00778. Epub 2020 Feb 19.
7
Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer.加拿大泌尿外科学会 - 加拿大泌尿肿瘤学组关于转移性去势初治和去势敏感性前列腺癌的指南
Can Urol Assoc J. 2020 Feb;14(2):17-23. doi: 10.5489/cuaj.6384. Epub 2019 Dec 5.
8
Vitamin D and Calcium for the Prevention of Fracture: A Systematic Review and Meta-analysis.维生素 D 和钙预防骨折：系统评价和荟萃分析。
JAMA Netw Open. 2019 Dec 2;2(12):e1917789. doi: 10.1001/jamanetworkopen.2019.17789.
9
Androgens and Androgen Receptor Actions on Bone Health and Disease: From Androgen Deficiency to Androgen Therapy.雄激素和雄激素受体对骨骼健康和疾病的作用：从雄激素缺乏到雄激素治疗。
Cells. 2019 Oct 25;8(11):1318. doi: 10.3390/cells8111318.
10
2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).2019年加拿大泌尿外科学会（CUA）-加拿大泌尿肿瘤学组（CUOG）指南：去势抵抗性前列腺癌（CRPC）的管理
Can Urol Assoc J. 2019 Oct;13(10):307-314. doi: 10.5489/cuaj.6136.
Zotero 插件